Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Common Equity (2024 - 2025)

Carlsmed (CARL) has disclosed Common Equity for 2 consecutive years, with $98.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 239.98% year-over-year to $98.9 million, compared with a TTM value of $98.9 million through Dec 2025, up 239.98%, and an annual FY2025 reading of $98.9 million, up 239.98% over the prior year.
  • Common Equity was $98.9 million for Q4 2025 at Carlsmed, down from $106.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $106.7 million in Q3 2025 and bottomed at -$83.1 million in Q2 2025.